The regulatory framework is now mature enough to create real friction. The FDA oversees AI-enabled medical devices and software as regulated products. U.S. patent law requires human inventors—not AI systems—to be named on patents, forcing companies to document human contribution rather than rely on algorithm outputs alone. HIPAA restricts how protected health information can be used for training and monitoring, including requirements around business-associate agreements and de-identification standards. Developers operating across state lines or with multiple health systems face compounding compliance obligations.
Attorneys advising healthcare AI vendors should treat this as a product-design problem, not a legal checkbox. Companies that coordinate patent strategy, FDA submission requirements, and HIPAA data governance early gain regulatory flexibility and patent strength. Those that do not risk losing both. The stakes are rising as FDA expectations for AI validation and post-market monitoring continue to harden and as courts and patent offices consistently enforce the human-inventorship standard. For in-house counsel, this means involving IP, regulatory, and privacy teams before engineering locks in architectural choices.